Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), Biocon has informed regarding the Commercial Launch of Yesafili™, a Biosimilar Aflibercept in the United States. The details required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as ‘Annexure A’. Further, Press Release titled ‘Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg’ is also enclosed as ‘Annexure B’. This intimation will also be available on website of the Company at www.biocon.com.
The above information is a part of company’s filings submitted to BSE.
